ALK-POSITIVE LARGE B-CELL LYMPHOMA
Clinical trials for ALK-POSITIVE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ALK-POSITIVE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for ALK-POSITIVE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cocktail aims to knock out tough lymphoma
Disease control Recruiting nowThis early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…
Matched conditions: ALK-POSITIVE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
New drug SGR-1505 enters early human testing for blood cancers
Disease control Recruiting nowThis early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…
Matched conditions: ALK-POSITIVE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Schrödinger, Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:11 UTC